🇺🇸 FDA
Patent

US 7998736

Adoptive immunotherapy with enhanced T lymphocyte survival

granted A61KA61K2039/55527A61K2239/57

Quick answer

US patent 7998736 (Adoptive immunotherapy with enhanced T lymphocyte survival) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/55527, A61K2239/57, A61K40/11, A61K40/35